Results 281 to 290 of about 115,048 (305)

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski   +2 more
exaly  

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Ca-A Cancer Journal for Clinicians, 2020
Enrica Marchi
exaly  

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Issues in emerging health technologies, 2005
Alemtuzumab, a humanized monoclonal antibody, is thought to destroy cancer cells through immune system stimulation or apoptosis induction (programmed cell death). In case series studies using alemtuzumab as salvage therapy, about a third of patients with B-cell chronic lymphocytic leukemia (B-CLL), who were otherwise refractory to chemotherapy ...
openaire   +1 more source

i(12q) in B-cell chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics, 1990
H, Xiao, A W, Block, J, Romano, B, Dadley, T, Han, A A, Sandberg   +5 more
openaire   +2 more sources

Chromosomal aberrations in chronic B-cell lymphocytic leukemia

Cancer Genetics and Cytogenetics, 1982
G, Gahrton, K H, Robèrt
openaire   +2 more sources

Karyotypic evolution of chronic lymphocytic leukemia B cells

Cancer Genetics and Cytogenetics, 1986
C L, Lee, L A, Fernandez, S H, Lee, T, Ghose   +3 more
openaire   +2 more sources

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Recent Progress in the Management of Advanced Renal Cell Carcinoma

Ca-A Cancer Journal for Clinicians, 2007
Brian I Rini, James Martin
exaly  

Oral cavity and oropharyngeal squamous cell carcinoma—an update

Ca-A Cancer Journal for Clinicians, 2015
exaly  

Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma

Ca-A Cancer Journal for Clinicians, 2010
Julie M Vose
exaly